Summary of Current Evidence on 5 IU or 10 IU Oxytocin Compared With Placebo
| Study | N | Route of Administration | Dose (IU) | RR for Blood Loss ≥500 cc (95% CI) | Other Clinically Important Endpoints: RR (95% CI) | Methodologic Issues |
|---|---|---|---|---|---|---|
| De Groot (1996)10 | 221 | IM | 5 | 0.83 (0.57, 1.22) | Blood loss ≥1000 cc: 0.80 (0.34, 1.87) Therapeutic uterotonic needed: 0.99 (0.55, 1.78) | Provisions for blinding not specified |
| Poeschmann (1991)11 | 52 | IM | 5 | 0.60 (0.27, 1.33) | Blood loss ≥1000 cc: 0.57 (0.10, 3.14) Therapeutic uterotonic needed: 0.17 (0.001, 3.42) | Trial ended early due to “organizational issues” |
| Pierre (1992)12 | 970 | IV | 5 | 0.29 (0.21, 0.41) | Blood loss ≥1000 cc: 0.33 (0.14, 0.77) | Allocation to treatment vs. control done even-odd, by order of registration Those measuring blood loss were not blinded to treatment status |
| Abdel-Aleem (2010)13 | 1,950 | IM | 10 | 0.53 (0.39, 0.74) | Blood loss ≥1000 cc: 0.52 (0.13, 2.08) Therapeutic uterotonic needed: 0.39 (0.26, 0.58) | |
| Nordstrom (1997)14 | 1,000 | IV | 10 | 0.56 (0.46, 0.70) | Blood loss ≥1000 cc: 0.71 (0.45, 1.10) Therapeutic uterotonic needed: 0.57 (0.39, 0.82) |